KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Non-Current Deferred Tax Liability (2016 - 2025)

Gsk (GSK) has 5 years of Non-Current Deferred Tax Liability data on record, last reported at $386.0 million in Q4 2023.

  • For Q4 2023, Non-Current Deferred Tax Liability rose 13.87% year-over-year to $386.0 million; the TTM value through Dec 2023 reached $386.0 million, up 13.87%, while the annual FY2023 figure was $386.8 million, 8.15% up from the prior year.
  • Non-Current Deferred Tax Liability reached $386.0 million in Q4 2023 per GSK's latest filing, up from $339.0 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $386.0 million in Q4 2023 and bottomed at $339.0 million in Q4 2022.